Table 1 The general characteristics of the included studies
Author | Year | Sudy design | Types of patients/years old | Participants | Number of case | Intervention | Gender (male/female)/case | Median age (range)/year | Dose of EPAG | EPAG duration month | Median follow-up time (range) /month | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPAG+IST | IST | EPAG+IST | IST | EPAG+IST | IST | EPAG+IST | IST | Introduce | Maximum | EPAG+IST | IST | ||||||
Assi [26] | 2018 | Cohort study | ≥ 18 | 38 | 21 | 17 | EPAG +hATG+CsA | hATG+CsA | 11/10 | 8/9 | 60 (19–84) | 53 (24–80) | 50 mg/day | 150 mg/day | ≥ 6 | 21 (3-49) | |
Chai [27] | 2021 | Cohort study | Elderly | 35 | 24 | 11 | EPAG +rATG+CsA | rATG+CsA | 15/9 | 5/6 | 66.5 (61–81) | 65 (61–72) | 25 mg/day | 75 mg/day | 3 or 6 | – | – |
De Latour [33] | 2022 | RCT | Unlimited | 197 | 96 | 101 | EPAG +hATG+CsA | hATG+CsA | 56/40 | 52/49 | 55 (16–77) | 52 (15–81) | 150 mg/day | 6 | 23 (19–24) | 24 (23–24) | |
Fang [28] | 2021 | Cohort study | < 18 | 57 | 18 | 39 | EPAG +pATG+CsA | pATG+CsA | 10/8 | 21/18 | 6.5 (1.2–12.5) | 7 (1.6–13.5) | 1 mg/kg/day | 50 mg/day | 6 | 31 (19–40) | 69 (41–103) |
Fang [36] | 2023 | RCT | Unlimited | 90 | 45 | 45 | EPAG +rATG+CsA | rATG+CsA | 23/22 | 25/20 | 36 (15–60) | 36 (15–59) | 25 mg/day | 75 mg/day | ≥ 4 | – | – |
Goronkova [38] | 2023 | RCT | < 18 | 98 | 49 | 49 | EPAG +hATG+CsA | hATG+CsA | 35/14 | 30/19 | 10.5 (2–17.7) | 8.7 (2.1–16.8) | 2 mg/kg/day | 3 or 6 | 26 (1–55) | 3 or 6 | |
Groarke [29] | 2021 | Cohort study | < 18 | 127 | 40 | 87 | EPAG +hATG+CsA | hATG+CsA | 23/17 | 51/36 | 13 (3–17) | 11 (2–17) | ≥ 12 years:150 mg/day 6–11 years:75 mg/day 2–5 years:25 mg/kg/day | ≥ 3 | 47 | 80 | |
Hu [37] | 2022 | Cohort study | Unlimited | 111 | 37 | 74 | EPAG +r/pATG+CsA | r/pATG+CsA | 24/13 | 34/40 | 33 (10-68) | 33 (10–68) | < 12 years:25 mg/day ≥ 12 years:50–75 mg/day | 150mg/d | – | – | – |
Jie [30] | 2021 | Cohort study | < 18 | 42 | 14 | 28 | EPAG +rATG+CsA | rATG+CsA | 8/6 | 14/15 | 7 (2–15.5) | 8 (4–14) | ≥ 6 years:75 mg/day 2–6 years:2.5 mg/kg/day | ≥ 6 | 28 (25–32) | 28.5 (1–88) | |
Jin [34] | 2022 | Cohort study | ≥ 18 | 121 | 54 | 67 | EPAG +rATG+CsA | rATG+CsA | 28/26 | 30/37 | 39 (18–74) | 40 (18–66) | 25 mg/day | 75 mg/day | – | 14 (1–79) | 16 (1–79) |
Lesmana [31] | 2021 | Cohort study | < 18 | 25 | 9 | 16 | EPAG +hATG+CsA | hATG+CsA | 7/2 | 4/12 | 11 (4–18) | 11.5 (1–17) | < 6 years:25 mg/day 6–18 years:50 mg/day | 150 mg/day | 6 | 15 (11–36) | 86 (4–132) |
Patel [35] | 2022 | Cohort study | Unlimited | 280 | 178 | 102 | EPAG +hATG+CsA | hATG+CsA | – | – | – | – | 150 mg/day | 3 or 6 | 48.7 (2.8–99.2) | 87.8 (2.9–190.8) | |
Zaimoku [8] | 2022 | Cohort study | Unlimited | 416 | 176 | 240 | EPAG +hATG+CsA | hATG+CsA | 87/89 | 141/99 | 32 (3–82) | 30 (2-82) | > 11 years:150 mg/day 6–11 years:75 mg/day 2–5 years:2.5 mg/kg/day | 6 | – | – | |
Zhang [32] | 2022 | Cohort study | < 18 | 63 | 31 | 32 | EPAG +rATG+CsA | rATG+CsA | 16/15 | 16/16 | 12 (8–16) | ≥ 27 kg:50 mg/day < 27 kg:1.5 mg/kg/day | 3.33–22.30 | – | – | ||
Zhao [39] | 2023 | Cohort study | < 18 | 60 | 15 | 45 | EPAG +r/pATG+CsA | r/pATG+CsA | 10/5 | 26/19 | 13 (4–18) | 13(7-17) | 2.5 mg/kg/day | 50 mg/day | 0.1–51 | 19 (7–34) | 74 (1–119) |
Shinn [40] | 2023 | Cohort study | ≥ 18 | 82 | 48 | 34 | EPAG +hATG+CsA | hATG+CsA | 25/23 | 18/16 | 54 (20–80) | 39.5 (18–76) | 150 mg/day | – | 18 (0.8–70) | 49 (0.4–93) | |